Cargando…

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review

BACKGROUND: The integrase strand transfer inhibitor dolutegravir (DTG) is being introduced into low- and middle-income countries (LMICs) as an alternative to first-line treatment with non-nucleoside reverse transcriptase inhibitors. However, DTG is not yet widely recommended for use in pregnant wome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hill, Andrew, Clayden, Polly, Thorne, Claire, Christie, Rachel, Zash, Rebecca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mediscript Ltd 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892677/ https://www.ncbi.nlm.nih.gov/pubmed/29682297

Ejemplares similares

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
por: Waitt, Catriona, et al.
Publicado: (2019)

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects
por: Mofenson, Lynne M, et al.
Publicado: (2019)

Engaging the community of women living with HIV to tailor and accelerate ARV research for pregnant and breastfeeding women
por: Clayden, Polly, et al.
Publicado: (2022)

Weight gain during pregnancy among women initiating dolutegravir in Botswana
por: Caniglia, Ellen C., et al.
Publicado: (2020)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Dolutegravir resistance in three pregnant and breastfeeding women in South Africa
por: Fourie, Ninke, et al.
Publicado: (2023)

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir
por: Vannappagari, Vani, et al.
Publicado: (2019)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

769. Mortality Among Inpatients After the Initiation of ‘Treat All’ With Dolutegravir in Botswana
por: Klinger, Amanda E, et al.
Publicado: (2020)

Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV
por: Banda, Clifford G., et al.
Publicado: (2022)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
por: Zash, Rebecca, et al.
Publicado: (2018)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
por: Kanters, Steve, et al.
Publicado: (2020)

Prevalence of depressive symptoms in pregnant and postnatal HIV-positive women in Ukraine: a cross-sectional survey
por: Bailey, Heather, et al.
Publicado: (2016)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
por: Song, Ivy H., et al.
Publicado: (2016)

Cross‐sectional trends in HIV prevalence among pregnant women in Botswana: an opportunity for PrEP?
por: Kapoor, Andrew, et al.
Publicado: (2022)

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
por: Kandel, Christopher E, et al.
Publicado: (2015)

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review
por: Townsend, Claire L., et al.
Publicado: (2022)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
por: Bollen, Pauline D J, et al.
Publicado: (2020)

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
por: Moore, Cecilia L., et al.
Publicado: (2021)

Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana
por: Liff, Ingrid, et al.
Publicado: (2020)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
por: Chandasana, Hardik, et al.
Publicado: (2023)

Incident HIV acquisition among pregnant women in Botswana: findings from the Tsepamo birth outcomes surveillance study
por: Mussa, Aamirah, et al.
Publicado: (2023)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Contraception use and HIV outcomes among women initiating dolutegravir‐containing antiretroviral therapy in Kenya: a retrospective cohort study
por: Humphrey, John M., et al.
Publicado: (2022)

Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV
por: Banda, Clifford G., et al.
Publicado: (2022)

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects
por: Song, Ivy, et al.
Publicado: (2015)

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol
por: Song, Ivy H., et al.
Publicado: (2015)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

Gynaecological morbidity among HIV positive pregnant women in Cameroon
por: Mbu, Enow R, et al.
Publicado: (2008)

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls
por: Song, Ivy H, et al.
Publicado: (2013)

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV
por: K, Priya Dharshini, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i6e4tq6tanli6cjvvildg8pcqr